VITA 34 AG (V3V) - Total Assets
Based on the latest financial reports, VITA 34 AG (V3V) holds total assets worth €168.26 Million EUR (≈ $196.71 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check VITA 34 AG investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
VITA 34 AG - Total Assets Trend (2006–2025)
This chart illustrates how VITA 34 AG's total assets have evolved over time, based on quarterly financial data. Explore V3V strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
VITA 34 AG - Asset Composition Analysis
Current Asset Composition (December 2025)
VITA 34 AG's total assets of €168.26 Million consist of 22.8% current assets and 77.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 7.1% |
| Accounts Receivable | €21.63 Million | 12.9% |
| Inventory | €3.15 Million | 1.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €14.01 Million | 8.3% |
| Goodwill | €32.64 Million | 19.4% |
Asset Composition Trend (2006–2025)
This chart illustrates how VITA 34 AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see V3V company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: VITA 34 AG's current assets represent 22.8% of total assets in 2025, a decrease from 30.4% in 2006.
- Cash Position: Cash and equivalents constituted 7.1% of total assets in 2025, down from 7.9% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 27.0% of total assets, a decrease from 48.0% in 2006.
- Asset Diversification: The largest asset category is goodwill at 19.4% of total assets.
VITA 34 AG Competitors by Total Assets
Key competitors of VITA 34 AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fresenius Medical Care AG & Co. KGaA
XETRA:FME
|
Germany | €31.47 Billion |
|
Ramsay Health Care Ltd
AU:RHC
|
Australia | AU$21.70 Billion |
|
PACS Group, Inc.
NYSE:PACS
|
USA | $5.66 Billion |
|
RAMSAY HLTH.CARE ADR/025
F:RMY0
|
Germany | €22.48 Billion |
|
Top Choice Medical Investment Co Inc
SHG:600763
|
China | CN¥6.24 Billion |
|
Sanbo Hospital Management Group Ltd. A
SHE:301293
|
China | CN¥3.72 Billion |
|
Xian International Medical Investment Co Ltd
SHE:000516
|
China | CN¥9.50 Billion |
|
MLP Saglik Hizmetleri AS
IS:MPARK
|
Turkey | TL89.94 Billion |
VITA 34 AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.66 | 0.73 | 1.76 |
| Quick Ratio | 0.61 | 0.68 | 1.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-19.31 Million | €-14.63 Million | €6.68 Million |
VITA 34 AG - Advanced Valuation Insights
This section examines the relationship between VITA 34 AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.20 |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | 10.2% |
| Total Assets | €168.26 Million |
| Market Capitalization | $71.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values VITA 34 AG's assets below their book value (0.42x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: VITA 34 AG's assets grew by 10.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for VITA 34 AG (2006–2025)
The table below shows the annual total assets of VITA 34 AG from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €168.26 Million ≈ $196.71 Million |
+10.16% |
| 2024-12-31 | €152.74 Million ≈ $178.57 Million |
-3.55% |
| 2023-12-31 | €158.36 Million ≈ $185.14 Million |
+4.52% |
| 2022-12-31 | €151.51 Million ≈ $177.13 Million |
-14.86% |
| 2021-12-31 | €177.95 Million ≈ $208.04 Million |
+204.37% |
| 2020-12-31 | €58.46 Million ≈ $68.35 Million |
-4.31% |
| 2019-12-31 | €61.10 Million ≈ $71.43 Million |
+3.00% |
| 2018-12-31 | €59.32 Million ≈ $69.35 Million |
-4.27% |
| 2017-12-31 | €61.96 Million ≈ $72.44 Million |
+42.69% |
| 2016-12-31 | €43.42 Million ≈ $50.76 Million |
-0.82% |
| 2015-12-31 | €43.78 Million ≈ $51.19 Million |
+18.15% |
| 2014-12-31 | €37.06 Million ≈ $43.32 Million |
+4.01% |
| 2013-12-31 | €35.63 Million ≈ $41.65 Million |
-2.73% |
| 2012-12-31 | €36.63 Million ≈ $42.82 Million |
+5.43% |
| 2011-12-31 | €34.74 Million ≈ $40.62 Million |
-5.31% |
| 2010-12-31 | €36.69 Million ≈ $42.89 Million |
+17.78% |
| 2009-12-31 | €31.15 Million ≈ $36.42 Million |
+2.78% |
| 2008-12-31 | €30.31 Million ≈ $35.43 Million |
-6.05% |
| 2007-12-31 | €32.26 Million ≈ $37.71 Million |
+24.99% |
| 2006-12-31 | €25.81 Million ≈ $30.17 Million |
-- |
About VITA 34 AG
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and… Read more